- Home
- PHAR vs SEAT Comparison
PHAR vs SEAT Comparison
Compare PHAR & SEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | SEAT |
|---|---|---|
| Founded | 1988 | 2001 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 82.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAR | SEAT |
|---|---|---|
| Price | $17.68 | $7.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $38.00 | $32.94 |
| AVG Volume (30 Days) | 26.8K | ★ 152.9K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | $362,274,000.00 | ★ $643,775,000.00 |
| Revenue This Year | $25.19 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $3,002.99 | ★ N/A |
| Revenue Growth | ★ 26.78 | N/A |
| 52 Week Low | $7.50 | $6.15 |
| 52 Week High | $18.30 | $100.00 |
Technical Indicators
Market Signals| Indicator | PHAR | SEAT |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 46.54 |
| Support Level | $16.55 | $6.21 |
| Resistance Level | $18.30 | $6.74 |
| Average True Range (ATR) | 0.80 | 0.53 |
| MACD | -0.07 | 0.16 |
| Stochastic Oscillator | 41.02 | 58.22 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.